Omnicell (NASDAQ:OMCL) was upgraded by Zacks Investment Research from a “strong sell” rating to a “hold” rating in a research note issued on Wednesday.

According to Zacks, “Omnicell's weak margin scenario is a matter of concern. The company lowering the high end of the full-year 2017 adjusted revenue guidance is indicative of this overall dull scenario to remain. A tough competitive landscape also acts as a dampener. Over the past month, Omnicell’s shares have been trading below the broader industry. However, on a positive note, the year-over-year increase in earnings and revenues was impressive. The company witnessed balanced growth across all its business lines in the quarter. We are encouraged to note that the company is working on product innovation through R&D. Over the recent past, Omnicell has been observed to gain consistently from series of product launches (the latest being XT Series Automated Supply Dispensing system) and strategic partnerships.”

Several other brokerages have also recently weighed in on OMCL. Oppenheimer reissued a “buy” rating and set a $55.00 price target on shares of Omnicell in a research report on Tuesday, December 5th. Craig Hallum reissued a “buy” rating and set a $62.00 price target (up previously from $52.00) on shares of Omnicell in a research report on Monday, October 30th. Cantor Fitzgerald increased their price target on shares of Omnicell to $58.00 and gave the company an “overweight” rating in a research report on Friday, October 27th. BidaskClub lowered shares of Omnicell from a “hold” rating to a “sell” rating in a report on Friday, December 22nd. Finally, Benchmark upped their price objective on shares of Omnicell from $55.00 to $67.00 and gave the stock a “buy” rating in a report on Tuesday, September 5th. One analyst has rated the stock with a sell rating, three have given a hold rating and six have issued a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $55.14.

Shares of Omnicell (NASDAQ:OMCL) traded up $0.10 on Wednesday, reaching $49.75. 77,377 shares of the company’s stock traded hands, compared to its average volume of 253,503. The stock has a market cap of $1,879.55, a PE ratio of -452.27, a P/E/G ratio of 26.22 and a beta of 0.71. The company has a quick ratio of 1.08, a current ratio of 1.53 and a debt-to-equity ratio of 0.38. Omnicell has a fifty-two week low of $31.85 and a fifty-two week high of $55.40.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings results on Thursday, October 26th. The company reported $0.42 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.42. The business had revenue of $186.78 million during the quarter, compared to analysts’ expectations of $192.45 million. Omnicell had a negative net margin of 0.51% and a negative return on equity of 0.79%. The firm’s revenue for the quarter was up 5.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.40 EPS. analysts predict that Omnicell will post 0.12 earnings per share for the current fiscal year.

In related news, CFO Peter J. Kuipers sold 1,926 shares of the stock in a transaction dated Monday, December 18th. The shares were sold at an average price of $51.69, for a total value of $99,554.94. Following the completion of the transaction, the chief financial officer now directly owns 40,544 shares in the company, valued at approximately $2,095,719.36. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP Peter J. Kuipers sold 4,724 shares of the stock in a transaction dated Friday, November 17th. The stock was sold at an average price of $47.74, for a total transaction of $225,523.76. Following the completion of the transaction, the vice president now owns 40,544 shares of the company’s stock, valued at $1,935,570.56. The disclosure for this sale can be found here. Insiders sold a total of 31,090 shares of company stock valued at $1,510,221 over the last 90 days. Company insiders own 3.77% of the company’s stock.

Institutional investors have recently modified their holdings of the stock. Janus Henderson Group PLC increased its stake in Omnicell by 129.6% during the 2nd quarter. Janus Henderson Group PLC now owns 1,231,933 shares of the company’s stock valued at $53,096,000 after purchasing an additional 695,334 shares in the last quarter. Principal Financial Group Inc. increased its stake in Omnicell by 124.9% during the 2nd quarter. Principal Financial Group Inc. now owns 660,803 shares of the company’s stock valued at $28,481,000 after purchasing an additional 367,019 shares in the last quarter. First Light Asset Management LLC increased its stake in Omnicell by 108.0% during the 2nd quarter. First Light Asset Management LLC now owns 278,294 shares of the company’s stock valued at $11,994,000 after purchasing an additional 144,471 shares in the last quarter. Eagle Asset Management Inc. increased its stake in Omnicell by 14.7% during the 3rd quarter. Eagle Asset Management Inc. now owns 998,107 shares of the company’s stock valued at $52,200,000 after purchasing an additional 127,873 shares in the last quarter. Finally, Pier Capital LLC bought a new stake in Omnicell during the 3rd quarter valued at about $5,488,000. Institutional investors own 99.61% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This news story was posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US & international trademark and copyright law. The legal version of this news story can be accessed at https://theolympiareport.com/2017/12/27/zacks-investment-research-upgrades-omnicell-omcl-to-hold.html.

Omnicell Company Profile

Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.

Analyst Recommendations for Omnicell (NASDAQ:OMCL)

Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.